Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Terminated
Baxter Healthcare Corporation
Phase 4
2001-10-01
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and
ceftazidime, administered intravenously as either thrice daily short infusions or 24 h
continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary
PA infection. In conventional treatment regimens, ceftazidime is administered in the form of
thrice daily short infusions, but pharmacodynamic considerations suggest that continuous
infusion could be more effective.
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Terminated
GlaxoSmithKline
Phase 4
2001-10-01
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and
ceftazidime, administered intravenously as either thrice daily short infusions or 24 h
continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary
PA infection. In conventional treatment regimens, ceftazidime is administered in the form of
thrice daily short infusions, but pharmacodynamic considerations suggest that continuous
infusion could be more effective.
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Terminated
Roche Pharma AG
Phase 4
2001-10-01
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and
ceftazidime, administered intravenously as either thrice daily short infusions or 24 h
continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary
PA infection. In conventional treatment regimens, ceftazidime is administered in the form of
thrice daily short infusions, but pharmacodynamic considerations suggest that continuous
infusion could be more effective.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
